<thead id="nhdrl"></thead>
<var id="nhdrl"><span id="nhdrl"></span></var><var id="nhdrl"></var><var id="nhdrl"><video id="nhdrl"></video></var>
<cite id="nhdrl"></cite>
<var id="nhdrl"></var>
<var id="nhdrl"></var>
<var id="nhdrl"><video id="nhdrl"><thead id="nhdrl"></thead></video></var>
CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)

Clinical Trials of Sirotinib (XZP - 5491) by CFDA with the Approval Numbers of 2016L06493 and 2016L06497. ...

Detail >
2016-08-04 15:252013-12-24 9:50
Phase II/ III Clinical Trials of Imigliptin Hydrochloride (KBP-3853) have been approved by CFDA; the Clinic...
2015-08-26 08:202013-12-24 9:50
Dr. Frank Wu (CEO, Shandong Xuanzhu Pharma Co., Ltd. and specially appointed National Thousand Talents Program...
2015-08-07 16:412013-12-24 9:50
CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209) today and more importantly granted us a...
2015-07-17 14:362013-12-24 9:50
IND filing of Sirotinib (XZP-5491), submitted at the end of June 2015, has been approved by CFDA (The filing numbers are CXHL1501499 and CXHL1501499).
2015-07-17 14:322013-12-24 9:50
On May 30th, the 2nd basketball tournament was held at XuanZhu. Seven teams from different divisions fough...
2015-06-16 08:172013-12-24 9:50
Pirotinib, a proprietary oncology drug developed by XuanZhu Pharma, has achieved a significant milestone - The fir...

Email | Terms of Use | Contact us

2014版权?轩竹医药科技有限公司保留所有权利 鲁ICP备09030169号